3 completed, 1 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Terminated 1 |
Follow Telik: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer Telcyta, Liposomal Doxorubicin - Ovarian Neoplasms | Phase 3 | Terminated | Telik | 244 | 2006-05-01 | 2013-11-27 |
| TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer TLK286 in Combination with Carboplatin, Doxorubicin HCl Liposome Injection - Ovarian Neoplasms | Phase 3 | Completed | Telik | 244 | 2004-12-01 | 2012-05-31 |
| TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection - Ovarian Neoplasms | Phase 3 | Completed | Telik | 440 | 2003-06-01 | 2011-07-25 |
| Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer TLK286 (Telcyta) HCl for Injection, gefitinib (Iressa) - Non Small Cell Lung Carcinoma | Phase 3 | Completed | Telik | 520 | 2008-01-15 |
Ovarian Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (1)
TER 286 (3) · Injections (2) · Carboplatin (1) · Gefitinib (1) · Topotecan (1) · liposomal doxorubicin (1)
United States (4) · Brazil (3) · United Kingdom (3) · Argentina (2) · Belgium (2) · Chile (2) · Germany (2) · Australia (1) · Czechia (1) · Hungary (1) · Ireland (1) · Italy (1) · Netherlands (1) · South Africa (1) · Spain (1)